Mainz Biomed B.V. (MYNZ)
3.31
-0.02 (-0.60%)
At close: Apr 14, 2025, 3:59 PM
3.37
1.70%
After-hours: Apr 14, 2025, 07:57 PM EDT
-0.60% (1D)
| Bid | 3.25 |
| Market Cap | 10.06M |
| Revenue (ttm) | 735.53K |
| Net Income (ttm) | -16.21M |
| EPS (ttm) | -22.36 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -0.56 |
| Analyst | Hold |
| Ask | 3.42 |
| Volume | 67,637 |
| Avg. Volume (20D) | 219,765 |
| Open | 3.34 |
| Previous Close | 3.33 |
| Day's Range | 3.27 - 3.45 |
| 52-Week Range | 0.18 - 8.20 |
| Beta | 0.53 |
About MYNZ
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Nov 5, 2021
Employees 19
Stock Exchange NASDAQ
Ticker Symbol MYNZ
Website https://mainzbiomed.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MYNZ stock is "Hold." The 12-month stock price forecast is $14, which is an increase of 322.96% from the latest price.
Stock Forecasts1 week ago
+17.41%
Mainz Biomed shares are trading higher on possible...
Unlock content with
Pro Subscription
2 months ago
+11.28%
Mainz Biomed shares are trading higher after the company announced through a partnership the launch of enhanced coloalert colorectal cancer screening.
